<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853655</url>
  </required_header>
  <id_info>
    <org_study_id>1713</org_study_id>
    <nct_id>NCT03853655</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy in Early Stage Oral Cancers</brief_title>
  <acronym>AREST</acronym>
  <official_title>Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tata Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the benefit of postoperative adjuvant radiotherapy in patients with an
      early oral squamous cell carcinoma (OSCC) having tumor thickness more than or equal to 5mm.
      The study population will consist of patients who have been treated by surgery for early
      stage oral tongue cancers. Patients with a close or positive margin (&lt;/= 5mm) and or with
      metastatic neck node(s) will be excluded. Selected patients will be randomized into two
      groups. The group I will be observed after surgery and group II will receive adjuvant
      radiotherapy as per protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to assess the benefit of postoperative adjuvant radiotherapy in
      patients with an early oral squamous cell carcinoma (OSCC) having a tumor depth of invasion
      more than or equal to 5mm.

      Primary objective:

      To determine the impact of postoperative adjuvant radiotherapy on locoregional
      recurrence-free survival in patients with early-stage oral tongue cancer with tumor thickness
      ≥ 5 mm.

      Secondary objectives:

        1. To compare disease-free survival and overall survival between the two groups.

        2. To assess and compare the quality of life changes between the two groups.

        3. To assess the acute and long-term radiation toxicity.

      We will be conducting a Phase III Open-Label Prospective Randomized Controlled Trial using
      stratified randomization. Patients will be randomized into two groups:

      Group I: Control arm (Observation only) Group II: Study arm (Postoperative adjuvant
      radiotherapy)

      Patients will be stratified on the following factors

        1. Presence of Perineural Invasion (PNI)/Lympho-Vascular Emboli (LVE)

        2. Histological grade (well-differentiated/moderately differentiated vs poorly
           differentiated)

        3. Tongue/Floor of Mouth vs Buccal Mucosa.

      Study procedures:

      The study population will consist of patients who have been treated by surgery for
      early-stage oral cancers. Patients satisfying the inclusion-exclusion criteria will be
      included in the study after obtaining a valid, written and informed consent. The depth of
      invasion will be assessed microscopically by measuring the maximum vertical bulk of the tumor
      from the normal mucosal surface to the deepest point of invasion. After reviewing the
      histopathological report, patients will be randomized to one of the 2 arms. Patients
      belonging to study arm (Group II) will receive adjuvant radiotherapy 60 Gray, 30 fractions
      for 30 days over 6 weeks as routinely prescribed at Tata Memorial Center (TMC) and will
      receive the treatment within or by 6 weeks after surgery.

      Both the groups (Group I and Group II) will be under regular follow-up with 3 monthly
      intervals for the first 2 years and 6 monthly for the next 3 years and once a year
      thereafter. At each follow-up, patients will be evaluated clinically for evidence of
      locoregional tumor recurrence. The locoregional recurrence-free survival will be calculated
      based on the difference between the date of randomization and the date of biopsy-proven
      recurrence. We will also record the overall survival in both groups. The quality of life will
      be assessed at each follow-up regular intervals using the European Organisation for Research
      and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ H&amp;N-35 ) and EORTC QLQ-C
      30. The radiation toxicity will be assessed using Common Terminology Criteria for Adverse
      Events (CTCAE) v4.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>loco-regional recurrence free survival</measure>
    <time_frame>Date of randomization to loco regional recurrence (date of proven biopsy date) or at the end of 36 months after recruitment of the last participant.</time_frame>
    <description>Measures the number of local or regional recurrences in both arm over a defined time frame.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Calculated as difference of date of randomization to date of first documented recurrence or relapse, second primary or death or at the end of 36 months after recruitment of the last participant.</time_frame>
    <description>time from the beginning of an intervention until patient experiences a recurrence, a new primary cancer or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Date of randomization to death from any cause or at the end of 36 months after recruitment of the last participant.</time_frame>
    <description>Date of Randomization to death from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life Measurement</measure>
    <time_frame>at Randomization, 3 months after completion of all treatments, 1 year, 2 years and 3 years after completion of all treatments.</time_frame>
    <description>Measured using EORTC QLQ H&amp;N-35 and EORTC QLQ-C 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute and long-term Radiation toxicity rate</measure>
    <time_frame>From the date of randomization until the date of first documented disease recurrence or date of death from any cause, assessed up to 36 months.</time_frame>
    <description>The Common Terminology Criteria for Adverse Events (CTCAE V 4.0) will be used for assessing the Adverse events. The Radiation Therapy Oncology Group (RTOG) acute and late radiation morbidity scoring criteria will be used for assessing the radiotherapy related toxicity.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Cancer of Mouth</condition>
  <condition>Cancer of the Tongue</condition>
  <condition>Cancer of the Head and Neck</condition>
  <condition>Buccal Mucosa Cancer</condition>
  <condition>Floor of Mouth Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will be observed and kept under active follow-up after surgery for the primary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Post-operative adjuvant radiotherapy</intervention_name>
    <description>Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.
Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.
Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks
For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week.</description>
    <arm_group_label>Study arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Post-operative early stage squamous cell carcinoma of the oral cavity (Oral Tongue,
             Buccal Mucosa, Floor of mouth). (pT1, pT2, N0 as defined in the AJCC Classification
             8th edition.

          2. Adequate surgery (Defined as wide local excision of the primary tumor with tumor-free
             margin ≥ 5mm and ipsilateral selective neck dissection addressing levels I-III at
             minimum.)

          3. Written informed consent.

          4. Age ≥18 years

          5. Eastern Co-operative Oncology Group (ECOG) Performance Status 0-2

          6. The depth of invasion (DOI) ≥ 5 mm.

          7. Compliance to therapy and follow-up

          8. The interval from surgery to adjuvant radiotherapy ≤ 6 weeks

        Exclusion Criteria:

          1. pT3/pT4 (as specified in the AJCC 8th edition).

          2. Depth of invasion &lt; 5mm.

          3. Any neck nodal metastasis with or without extra nodal extension

          4. Tumor-free margin &lt; 5 mm

          5. Non-squamous histology

          6. Pregnant woman

          7. Prior h/o any other malignancy in the last five years

          8. Prior therapeutic irradiation of the head and neck.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudhir V Nair, MS, MCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sudhir V Nair, MS, MCh</last_name>
    <phone>912224177283</phone>
    <email>sudhirvr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tejpal Gupta, MD</last_name>
    <phone>919821548980</phone>
    <email>tejpalgupta@rediffmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. B Barooah Cancer Institute</name>
      <address>
        <city>Guwahati</city>
        <state>Assam</state>
        <zip>781016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashok Das, MS</last_name>
      <email>akdas171@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCG Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajendra Toprani, MCh</last_name>
      <email>rajendratoprani@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mazumdar Shaw Medical Centre</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560100</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narayana Subramaniam, MS, MCh</last_name>
      <email>narayana.subramaniam@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Narayana Subramaniam, MS,MCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naveen H Chandrasekhar, MS,MCh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandeep Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subramania Iyer, MCh</last_name>
      <email>subu.amrita@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Subramania Iyer, MS, MCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhir V Nair, MBBS, MS</last_name>
      <phone>912224177000</phone>
      <phone_ext>7283</phone_ext>
      <email>sudhirvr@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tejpal Gupta, MBBS, MD</last_name>
      <phone>919821548980</phone>
      <email>tejpalgupta@rediffmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sudhir V Nair, MS,MCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tejpal Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarbani Laskar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pankaj Chaturvedi, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Devendra Chaukar, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anil K D'Cruz, MS,FRCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Adyar</name>
      <address>
        <city>Adyar</city>
        <state>Tamil Nadu</state>
        <zip>600020</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arvind Krishnamurthy, MS, MCh</last_name>
      <email>drarvindkrishnamurthy@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>https://seer.cancer.gov/archive/csr/1975_2010/</url>
    <description>SEER Cancer statistics review 1975-2010. National cancer institute</description>
  </link>
  <reference>
    <citation>Thiagarajan S, Nair S, Nair D, Chaturvedi P, Kane SV, Agarwal JP, D'Cruz AK. Predictors of prognosis for squamous cell carcinoma of oral tongue. J Surg Oncol. 2014 Jun;109(7):639-44. doi: 10.1002/jso.23583. Epub 2014 Mar 12.</citation>
    <PMID>24619660</PMID>
  </reference>
  <reference>
    <citation>Dequanter D, Saint-Aubin N, Paesmans M, Badr-El-Din A, Lothaire P, Andry G. [Prognostic factors in epidermoid carcinoma of the mobile tongue classified as T1-T2]. Ann Otolaryngol Chir Cervicofac. 2001 Oct;118(5):315-22. French.</citation>
    <PMID>11845040</PMID>
  </reference>
  <reference>
    <citation>Kokemueller H, Rana M, Rublack J, Eckardt A, Tavassol F, Schumann P, Lindhorst D, Ruecker M, Gellrich NC. The Hannover experience: surgical treatment of tongue cancer--a clinical retrospective evaluation over a 30 years period. Head Neck Oncol. 2011 May 21;3:27. doi: 10.1186/1758-3284-3-27.</citation>
    <PMID>21600000</PMID>
  </reference>
  <reference>
    <citation>Ganly I, Patel S, Shah J. Early stage squamous cell cancer of the oral tongue--clinicopathologic features affecting outcome. Cancer. 2012 Jan 1;118(1):101-11. doi: 10.1002/cncr.26229. Epub 2011 Jun 29.</citation>
    <PMID>21717431</PMID>
  </reference>
  <reference>
    <citation>Gonzalez-Moles MA, Esteban F, Rodriguez-Archilla A, Ruiz-Avila I, Gonzalez-Moles S. Importance of tumour thickness measurement in prognosis of tongue cancer. Oral Oncol. 2002 Jun;38(4):394-7.</citation>
    <PMID>12076706</PMID>
  </reference>
  <reference>
    <citation>Huang SF, Kang CJ, Lin CY, Fan KH, Yen TC, Wang HM, Chen IH, Liao CT, Cheng AJ, Chang JT. Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer. 2008 Mar 1;112(5):1066-75. doi: 10.1002/cncr.23278.</citation>
    <PMID>18246535</PMID>
  </reference>
  <reference>
    <citation>Shim SJ, Cha J, Koom WS, Kim GE, Lee CG, Choi EC, Keum KC. Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy. Radiat Oncol. 2010 May 27;5:43. doi: 10.1186/1748-717X-5-43.</citation>
    <PMID>20504371</PMID>
  </reference>
  <reference>
    <citation>Caramello P, Giacobbi D, Savoia D. [Identification of Pneumocystis carinii in a patient dying of AIDS]. G Batteriol Virol Immunol. 1985 Jul-Dec;78(7-12):171-7. Italian.</citation>
    <PMID>3879892</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tata Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Sudhir Nair</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cancer of the Mouth</keyword>
  <keyword>Tongue cancer</keyword>
  <keyword>Buccal Mucosa cancer</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Oral Cancer</keyword>
  <keyword>Adjuvant Radiotherapy</keyword>
  <keyword>Depth of Invasion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

